DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville, MD 20857

NDA 20-388/S-014

SmithKlineBeecham Corporation d/b/a GlaxoSmithKline
2301 Renaissance Boulevard RN0210
Building 510, P.O. Box 61540
King of Prussia, PA 19406-2772

ATTN: Anne-Margaret Martin
Senior Director, US Regulatory Affairs, Oncology

Dear Ms. Martin:

Please refer to your supplemental new drug application dated June 17, 2002, received June 18, 2002, submitted under section 505A of the Federal Food, Drug, and Cosmetic Act for Navelbine (vinorelbine tartrate) Injection.

We acknowledge receipt of your submission dated June 28, 2002.

This supplemental new drug application provides for pediatric study reports and pediatric exclusivity determination.

We have completed our review of this application, as amended. This application is approved, effective on the date of this letter, for use as recommended in the September 6, 2002 agreed upon labeling text.

The final printed labeling (FPL) must be identical to the enclosed agreed upon labeling text for the package insert.

Please submit the FPL electronically according to the guidance for industry titled Providing Regulatory Submissions in Electronic Format – NDA. Alternatively, you may submit 20 paper copies of the FPL as soon as it is available, in no case more than 30 days after it is printed. Please individually mount ten of the copies on heavy-weight paper or similar material. For administrative purposes, this submission should be designated as "FPL for approved supplement NDA 20-388/S-014". Approval of this submission by FDA is not required before the labeling is used.

If you issue a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HF-2
FDA
5600 Fishers Lane
Rockville, MD 20857

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Maureen A. Pelosi, Regulatory Project Manager, at (301) 594-5778.

Sincerely,

{See appended electronic signature page}

Richard Pazdur, M.D.
Division Director
Division of Oncology Drug Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Richard Pazdur

11/5/02 04:53:30 PM